首页> 外文期刊>Autoimmunity reviews >New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis
【24h】

New use for an old treatment: Hydroxychloroquine as a potential treatment for systemic vasculitis

机译:旧治疗的新用途:羟氯喹作为全身血管炎的潜在治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Antimalarials have been an effective and safe treatment for autoimmune rheumatic diseases such as systemic lupus erythematosus for more than a hundred years. There are surprisingly few reports of hydroxychloroquine use in the systemic vasculitides. Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events. We report the successful use of hydroxychloroquine in patients with ANCA vasculitis, Henoch Schonlein purpura/IgA vasculitis, Takayasu's arteritis and polyarteritis nodosa. We review the immunomodulatory mechanisms of action of hydroxychloroquine and the existing evidence for its use in the treatment of vasculitis, with a particular focus on ANCA subtypes. (C) 2018 Published by Elsevier B.V.
机译:Alimalarials对自身免疫性风湿性疾病(如Systemic Lupus红斑)超过一百年的有效和安全的治疗。 令人惊讶的是,羟基氯喹在全身血管素中使用的报道很少。 羟基氯喹有抗血栓形成,心血管,抗微生物和抗肿瘤效果,使其具有患有感染风险,恶性肿瘤和血栓性事件的全身血管炎患者的潜在有价值的治疗方法。 我们举报了羟基氯喹对ANCA血管炎患者的成功使用,Henoch Schonlein Purpura / IgA血管炎,高山的动脉炎和多种动脉炎。 我们审查了羟基氯喹的免疫调节机制以及用于治疗血管炎的现有证据,特别关注ANCA亚型。 (c)2018由elsevier b.v发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号